Thyroid UK has seen a response from NHS England in regard to the question of whether T3 has already been de-prescribed even though the consultation does not end until October, something that has had us all very concerned over the past few days. Their response was:
An NHS England spokesperson said:
“NHS England is currently consulting on proposals - drawn up with family doctors and pharmacists – to cut out prescriptions for ineffective, over-priced and low value treatments. There has been no change to national commissioning guidance whilst this consultation is underway. Helping to trim hundreds of millions from the nation’s rapidly growing drugs bill will create headroom to reinvest all savings in newer and more effective NHS medicines and treatments.”
Final guidance on any restrictions to the drugs under review will be informed by responses to the consultation, once they have been fully analysed and considered.
NHS England has been working with NHS Clinical Commissioners on proposals to issue national commissioning guidance on “Items which should not routinely be prescribed in primary care”, and this particular product (liothyronine) is included in that proposed guidance.
CCGs are able to develop their own prescribing policies and advice for their prescribers locally. Once the final national guidance is published, CCGs will need to have due regard to these changes.
This doesn't mean we can rest on our laurels. Let's fight this injustice!